Wenbin Jiang - 18 May 2022 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role
President and CEO, Director
Signature
/s/ Valerie Barnett, Attorney-in-Fact for Wenbin Jiang
Issuer symbol
CTKB
Transactions as of
18 May 2022
Transactions value $
-$33,872
Form type
4
Filing time
20 May 2022, 19:15:10 UTC
Previous filing
12 May 2022
Next filing
09 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTKB Common Stock Options Exercise +9.01K +0.11% 7.91M 18 May 2022 Direct F1
transaction CTKB Common STock Tax liability -$33.9K -3.51K -0.04% $9.65 7.9M 18 May 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTKB Restricted Stock Units Options Exercise $0 -9.01K -8.33% $0.00 99.1K 18 May 2022 Common Stock 9.01K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2 Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
F3 The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.